Mosapride belongs to class IV in Biopharmaceutics Classification System and is used in the treatment of reflux esophagitis. It exhibits poor bioavailability due to limited permeability, solubility and extensive first-pass metabolism. In this study, intranasal mosapride-loaded cross-linked xyloglucan Pluronic micelles (MOS-XPMs) was formulated and optimized to improve the low solubility & bioavailability of MOS. The solid dispersion technique using 23 full factorial design was applied. (MOS-XPMs) (F4) had the highest desirability value () and, therefore, it was selected as an optimal system. Xyloglucan cross-linked in the shell of Pluronic micelles offered improved stability and mucoadhesiveness to MOSXPMs. 1 H NMR spectra ensured the cross-linking of xyloglucan with Pluronic micelle shell and micelle stabilization. | New intranasal cross-linked mosapride xyloglucan pluronics micelles MOS-XPMs for reflux esophagitis disease In-vitro optimization and improved therapeutic efficacy
